Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Coherus Oncology (CHRS) Return on Invested Capital (2019 - 2023)

Coherus Oncology (CHRS) has disclosed Return on Invested Capital for 4 consecutive years, with 1.27% as the latest value for Q4 2023.

  • Quarterly Return on Invested Capital changed N/A to 1.27% in Q4 2023 from the year-ago period, while the trailing twelve-month figure was 1.27% through Dec 2023, changed N/A year-over-year, with the annual reading at 1.24% for FY2023, N/A changed from the prior year.
  • Return on Invested Capital hit 1.27% in Q4 2023 for Coherus Oncology, up from 1.22% in the prior quarter.
  • In the past five years, Return on Invested Capital ranged from a high of 1.27% in Q4 2023 to a low of 0.56% in Q3 2021.
  • Historically, Return on Invested Capital has averaged 0.42% across 4 years, with a median of 0.51% in 2020.
  • Biggest five-year swings in Return on Invested Capital: skyrocketed 59bps in 2020 and later plummeted -114bps in 2021.
  • Year by year, Return on Invested Capital stood at 0.86% in 2019, then tumbled by -49bps to 0.44% in 2020, then plummeted by -227bps to 0.56% in 2021, then skyrocketed by 327bps to 1.27% in 2023.
  • Business Quant data shows Return on Invested Capital for CHRS at 1.27% in Q4 2023, 1.22% in Q3 2023, and 0.56% in Q3 2021.